McKesson (NYSE:MCK) Releases FY 2025 Earnings Guidance

McKesson (NYSE:MCK - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 32.400-33.000 for the period, compared to the consensus EPS estimate of 36.680. The company issued revenue guidance of -. McKesson also updated its FY25 guidance to $32.40-33.00 EPS.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on MCK shares. Mizuho started coverage on McKesson in a research report on Wednesday, December 4th. They set a "neutral" rating and a $630.00 price target on the stock. Citigroup lowered their price objective on shares of McKesson from $713.00 to $677.00 and set a "buy" rating for the company in a research note on Friday, January 10th. StockNews.com raised shares of McKesson from a "hold" rating to a "buy" rating in a research report on Wednesday, November 6th. Leerink Partners lowered their price target on shares of McKesson from $665.00 to $630.00 and set an "outperform" rating for the company in a research report on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on shares of McKesson from $623.00 to $579.00 and set a "buy" rating on the stock in a report on Wednesday, September 25th. Two equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, McKesson currently has a consensus rating of "Moderate Buy" and a consensus target price of $646.14.

McKesson Stock Down 1.7 %

Shares of McKesson stock traded down $10.22 during trading on Wednesday, reaching $583.51. The company's stock had a trading volume of 722,346 shares, compared to its average volume of 651,002. McKesson has a 1-year low of $464.42 and a 1-year high of $637.51. The company has a 50-day simple moving average of $595.09 and a two-hundred day simple moving average of $560.90. The company has a market cap of $74.07 billion, a price-to-earnings ratio of 30.22, a P/E/G ratio of 1.25 and a beta of 0.52.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share for the quarter, topping the consensus estimate of $6.88 by $0.19. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The business had revenue of $93.65 billion during the quarter, compared to the consensus estimate of $89.33 billion. During the same quarter last year, the company earned $6.23 earnings per share. The company's quarterly revenue was up 21.3% on a year-over-year basis. As a group, analysts anticipate that McKesson will post 32.73 earnings per share for the current year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $2.84 dividend on an annualized basis and a yield of 0.49%. McKesson's payout ratio is 14.71%.

Insiders Place Their Bets

In related news, EVP Leann B. Smith sold 579 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the transaction, the executive vice president now directly owns 864 shares of the company's stock, valued at $494,890.56. This represents a 40.12 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.11% of the company's stock.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.